BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis Showcases Impact Of VOXZOGO In Foramen Magnum And Craniocervical Junction Growth
The data include encouraging new imaging results from a post-hoc analysis of a randomized, double-blind, placebo-controlled trial evaluating the effect of VOXZOGO on the growth of the foramen magnum and craniocervical
BioMarin is sharing new study results about medicines for rare bone growth conditions. When a company presents good data, it shows progress toward helping patients and maybe future sales.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.